Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/shingrixhttps://www.ema.europa.eu/en/medicines/human/EPAR/shingrix
Retrieved on: 
Tuesday, January 2, 2024
Information
Tags: 
People, Chills, Patient, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Fever, Fatigue, Shingles, Human, ATC, Antibody, Bone marrow, Pain, Chronic pain, International, Injection, Headache, Disease, Ageing, Nausea, Language, HZ, Vaccination, Swelling, Red, PHN, Trigeminal neuralgia, European Medicines Agency, Chickenpox, Myalgia, Select, Anatomy, Vomiting, IIA, Vaccine
Geotags: 
EU
Summary
Key Points: 


Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.